111 related articles for article (PubMed ID: 20067943)
1. Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.
Elliott ES; Purvis TL; Nelson LA; Sommi RW
J Clin Pharmacol; 2010 Jun; 50(6):721-4. PubMed ID: 20067943
[No Abstract] [Full Text] [Related]
2. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
4. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
[TBL] [Abstract][Full Text] [Related]
5. [Risperidone injection. Deltoid muscle or buttocks?].
Laberge L
Perspect Infirm; 2010; 7(6):43-4. PubMed ID: 21141635
[No Abstract] [Full Text] [Related]
6. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
7. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?
Seto K; Dumontet J; Ensom MH
Ther Drug Monit; 2011 Jun; 33(3):275-83. PubMed ID: 21436762
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
Hough D; Lindenmayer JP; Gopal S; Melkote R; Lim P; Herben V; Yuen E; Eerdekens M
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):1022-31. PubMed ID: 19481579
[TBL] [Abstract][Full Text] [Related]
9. Patients' acceptance of the deltoid application of risperidone long-acting injection.
Heres S; Frobose T; Hamann J; Leucht S; Maino K; Reichhart T; Stiegler M; Kissling W
Eur Neuropsychopharmacol; 2012 Dec; 22(12):897-901. PubMed ID: 22578781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
11. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.
Volonteri LS; Cerveri G; De Gaspari IF; Baldi ML; Rolandi ML; Papa P; Mauri MC; Mencacci C
Psychopharmacology (Berl); 2010 Jul; 210(4):489-97. PubMed ID: 20422405
[TBL] [Abstract][Full Text] [Related]
12. Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
Marder SR; Conley R; Ereshefsky L; Kane JM; Turner MS
J Clin Psychiatry; 2003; 64 Suppl 16():41-6. PubMed ID: 14680418
[No Abstract] [Full Text] [Related]
13. [Study on how schizophrenic patients perceive treatment with injections in the deltoid muscle].
Millet B; Gourevitch R; Levoyer D; Parmentier G; Joly C
Encephale; 2012 Feb; 38(1):97-103. PubMed ID: 22381729
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
15. Risperidone long-acting injection in practice - more questions than answers?
Taylor D
Acta Psychiatr Scand; 2006 Jul; 114(1):1-2. PubMed ID: 16774654
[No Abstract] [Full Text] [Related]
16. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
17. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
18. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
19. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
20. Is depot medication safe in the setting of myopathy?
Price JR; Bastiampillai T; Dhillon RS
Aust N Z J Psychiatry; 2009 Aug; 43(8):781-3. PubMed ID: 19629801
[No Abstract] [Full Text] [Related]
[Next] [New Search]
